SCHEMBL3351733

SCHEMBL3351733

CONc1ncnc2ccc(OCCCN3CCOCC3)cc12

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRC P12931 7/20 0.58
ALDH1A1 P00352 3/20 0.57
KDR P35968 3/20 0.54
KDM4E B2RXH2 1/20 0.53
CYP1A2 P05177 3/20 0.53
USP2 O75604 2/20 0.53
CYP3A4 P08684 2/20 0.53
CYP2D6 P10635 2/20 0.53
CLK4 Q9HAZ1 2/20 0.53
SIGMAR1 Q99720 2/20 0.51
CHRM2 P08172 1/20 0.51
CHRM1 P11229 1/20 0.51
HTR2A P28223 1/20 0.51
MAPK1 P28482 1/20 0.51
SCN1A P35498 1/20 0.51
HTR2B P41595 1/20 0.51
KCNH2 Q12809 1/20 0.51
SCN2A Q99250 1/20 0.51
SCN3A Q9NY46 1/20 0.51
HRH3 Q9Y5N1 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL239668 0.81 SIGMAR1 (0.56) SRCALDH1A1KDRCYP1A2USP2
SCHEMBL7763005 0.80 EGFR (0.61) SRCKDRKCNH2HRH3EGFR
SCHEMBL12474209 0.80 EGFR (0.55) SRCKDRKCNH2HRH3EGFR
SCHEMBL31331907 0.79 EGFR (0.65) SRCKDRKCNH2HRH3EGFR
SCHEMBL7766288 0.78 EGFR (0.73) SRCKDRKCNH2HRH3EGFR
SCHEMBL31385612 0.75 MEN1 (0.53) ALDH1A1CYP1A2SIGMAR1CHRM2CHRM1
SCHEMBL12694372 0.75 AURKA (0.74) SRCALDH1A1KDREGFRILK
SCHEMBL4759642 0.75 SRC (0.60) SRCALDH1A1KDRCYP1A2USP2
SCHEMBL30783040 0.74 SRC (0.55) SRCALDH1A1KDRCYP1A2USP2
SCHEMBL4429202 0.74 SRC (0.55) SRCALDH1A1KDRCYP1A2USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2009090661-A9 6.7-DIALKOXY OUINAZOLINE DERIVATIVES USEFUL FOR TREATMENT OF CANCER RELATED DISORDERS NATCO PHARMA LIMITED (IN) 2010-06-17 WO disclosed